Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Cecilia Ayala-Zambrano"'
Autor:
Benilde García-de Teresa, Cecilia Ayala-Zambrano, Mirna González-Suárez, Bertha Molina, Leda Torres, Alfredo Rodríguez, Sara Frías
Publikováno v:
PLoS ONE, Vol 19, Iss 5, p e0298032 (2024)
The FA/BRCA pathway safeguards DNA replication by repairing interstrand crosslinks (ICL) and maintaining replication fork stability. Chromatin structure, which is in part regulated by histones posttranslational modifications (PTMs), has a role in mai
Externí odkaz:
https://doaj.org/article/4057846f40924129aa6fd79c96e95f03
Autor:
Alfredo Rodríguez, Michael Epperly, Jessica Filiatrault, Martha Velázquez, Chunyu Yang, Kelsey McQueen, Larissa A Sambel, Huy Nguyen, Divya Ramalingam Iyer, Ulises Juárez, Cecilia Ayala-Zambrano, David B Martignetti, Sara Frías, Renee Fisher, Kalindi Parmar, Joel S Greenberger, Alan D D'Andrea
Publikováno v:
PLoS Genetics, Vol 18, Iss 11, p e1010459 (2022)
Overexpression of the TGFβ pathway impairs the proliferation of the hematopoietic stem and progenitor cells (HSPCs) pool in Fanconi anemia (FA). TGFβ promotes the expression of NHEJ genes, known to function in a low-fidelity DNA repair pathway, and
Externí odkaz:
https://doaj.org/article/3b6810ea3d60476997167f0422bc2836
Autor:
Alfredo Rodríguez, J. Jesús Naveja, Leda Torres, Benilde García de Teresa, Ulises Juárez-Figueroa, Cecilia Ayala-Zambrano, Eugenio Azpeitia, Luis Mendoza, Sara Frías
Publikováno v:
Frontiers in Genetics, Vol 10 (2019)
DNA damage adaptation (DDA) allows the division of cells with unrepaired DNA damage. DNA repair deficient cells might take advantage of DDA to survive. The Fanconi anemia (FA) pathway repairs DNA interstrand crosslinks (ICLs), and deficiencies in thi
Externí odkaz:
https://doaj.org/article/9710ac1211f347bfb107529721d0be3f
Autor:
Alexandre Andre B. A. Da Costa, Arindam Bose, David Martignetti, Cecilia Ayala-Zambrano, Ramya Ravindranathan, Golbahar Sadatrezaei, Yuqing Jiao, Bose Kochupurakkal, Huy Nguyen, Jean-Bernard Lazaro, Kalindi Parmar, Geoffrey I. Shapiro, Alan D. D’Andrea
Publikováno v:
Cancer Research. 83:5725-5725
Targeting BRCA-deficient tumors with PARP inhibitors has improved the progression-free survival of ovarian and breast cancer patients in the clinic. However, the majority of patients develop acquired resistance. PARP inhibitor (PARPi) resistance in t